Amicogen's partner Lysando AG to supply would spray to Kuwait and Gulf states

Lysando AG, a Switzerland-based biotech company and partner of the Korean firm Amicogen, said on Monday that it has signed a contract to supply Kuwait with its wound treatment product, Medolysin Wound Spray.  

The agreement with Al-Sareh International General Trading Company, which serves the Kuwait market with healthcare, scientific and educational equipment and supplies, extends to member countries of the Cooperation Council for the Arab States of the Persian Gulf (CCASG), with potential for future expansion.

Medolysin, developed through Lysando AG's proprietary Artilysin technology, contains endolysin, a natural antibiotic derived from bacteriophages that destroy pathogens by breaking down their cell walls. It protects compromised skin barriers by forming a protective film on wounds, eliminating pathogens, and reducing inflammation. Unlike conventional antibiotic therapies, Medolysin’s mechanism of action addresses infected wounds and offers a solution to the growing problem of multidrug resistance.

“As enzymes, they are safe for the human immune system and do not lead to resistance like antibiotics,” an Amicogen spokesperson explained. “Crucially, endolysins selectively target and kill pathogens, leaving beneficial bacteria in the body unharmed.”

Commercialization of Medolysin was previously challenging due to low productivity, but recent advancements have doubled productivity compared to existing CMO companies, paving the way for broader commercialization, the Amicogen spokesperson added.

Lysando AG is a German-owned company headquartered in Switzerland with R&D and sales centers in Germany, specializing in endolysin technology. With 260 international patents and 450 candidate compounds, the company is at the forefront of developing next-generation antibiotics, Amicogen said. 

As Lysando AG's CDMO partner, Amicogen will exclusively produce and supply Medolysin. This collaboration is poised to play a pivotal role in introducing advanced wound care products to the Middle East and global markets.

The Middle East has been investing heavily in new technologies and innovative products to strengthen its healthcare infrastructure. According to Amicogen, the wound care market in the region was valued at approximately $100 million in 2021 and is expected to grow at a robust CAGR of 6-8 percent.

Lysando AG's Medolysin, produced by Amicogen, is gaining recognition as a novel solution for treating chronic inflammation caused by infections. The expanding wound care market in the Middle East, coupled with the introduction of products like Medolysin, is expected to “significantly improve patients' quality of life,” said Amicogen.